Aimmune Therapeutics Inc. (NASDAQ:AIMT) – Wedbush decreased their FY2016 earnings estimates for shares of Aimmune Therapeutics in a report issued on Tuesday. Wedbush analyst L. Moussatos now expects that the firm will post earnings per share of ($1.80) for the year, down from their previous estimate of ($1.70). Wedbush has a “Outperform” rating and a $42.00 price objective on the stock. Wedbush also issued estimates for Aimmune Therapeutics’ FY2017 earnings at ($2.03) EPS, FY2018 earnings at ($2.22) EPS, FY2019 earnings at ($1.18) EPS and FY2020 earnings at $1.41 EPS.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Monday, November 14th. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.08.

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Other equities research analysts also recently issued research reports about the company. Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 price target on shares of Aimmune Therapeutics in a report on Friday, August 19th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, September 19th. JMP Securities started coverage on Aimmune Therapeutics in a report on Monday, September 26th. They set an “outperform” rating and a $30.00 price target for the company. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 price target on shares of Aimmune Therapeutics in a report on Friday, September 23rd. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $32.20.

Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.9122% during midday trading on Thursday, hitting $25.9748. The stock had a trading volume of 214,320 shares. The stock has a market cap of $1100.89 billion, a P/E ratio of 11.3925 and a beta of -1.80. Aimmune Therapeutics has a 52 week low of $9.77 and a 52 week high of $27.31. The company has a 50-day moving average price of $18.13 and a 200-day moving average price of $14.67.

Several hedge funds and other institutional investors have recently modified their holdings of AIMT. Eagle Asset Management Inc. boosted its position in shares of Aimmune Therapeutics by 12.9% in the second quarter. Eagle Asset Management Inc. now owns 1,988,434 shares of the company’s stock worth $21,514,000 after buying an additional 227,439 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Aimmune Therapeutics by 4.5% in the second quarter. American Century Companies Inc. now owns 98,261 shares of the company’s stock worth $1,063,000 after buying an additional 4,201 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Aimmune Therapeutics by 24.9% in the second quarter. Alps Advisors Inc. now owns 59,351 shares of the company’s stock worth $642,000 after buying an additional 11,837 shares in the last quarter. Emerald Mutual Fund Advisers Trust boosted its position in shares of Aimmune Therapeutics by 1.2% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 332,625 shares of the company’s stock worth $3,599,000 after buying an additional 3,970 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Aimmune Therapeutics by 60.8% in the second quarter. Bank of New York Mellon Corp now owns 82,661 shares of the company’s stock worth $895,000 after buying an additional 31,245 shares in the last quarter. 70.49% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Mary M. Rozenman sold 25,000 shares of the company’s stock in a transaction on Wednesday, October 5th. The stock was sold at an average price of $16.80, for a total transaction of $420,000.00. Following the transaction, the insider now owns 25,000 shares of the company’s stock, valued at approximately $420,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mary M. Rozenman sold 24,096 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $17.60, for a total value of $424,089.60. Following the transaction, the insider now directly owns 24,096 shares in the company, valued at approximately $424,089.60. The disclosure for this sale can be found here. 24.56% of the stock is owned by company insiders.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.